0001104659-23-066016.txt : 20230530 0001104659-23-066016.hdr.sgml : 20230530 20230530161009 ACCESSION NUMBER: 0001104659-23-066016 CONFORMED SUBMISSION TYPE: SD PUBLIC DOCUMENT COUNT: 1

13p-1

1.01 20221231

FILED AS OF DATE: 20230530 DATE AS OF CHANGE: 20230530 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Teladoc Health, Inc. CENTRAL INDEX KEY: 0001477449 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE [8011] IRS NUMBER: 043705970 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SD SEC ACT: 1934 Act SEC FILE NUMBER: 001-37477 FILM NUMBER: 23976426 BUSINESS ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 BUSINESS PHONE: 2036352002 MAIL ADDRESS: STREET 1: 2 MANHATTANVILLE ROAD STREET 2: SUITE 203 CITY: PURCHASE STATE: NY ZIP: 10577 FORMER COMPANY: FORMER CONFORMED NAME: Teladoc, Inc. DATE OF NAME CHANGE: 20091123 SD 1 tm2316392d1_sd.htm FORM SD

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM SD

SPECIALIZED DISCLOSURE REPORT

Teladoc Health, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37477	04-3705970
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2 Manhattanville Road, Suite 203

Purchase, New York

10577

(Address of Principal Executive Offices)

(Zip Code)

Adam C. Vandervoort

Chief Legal Officer and Secretary

(203) 635-2002

(Name and telephone number, including area code, of the person to contact in connection with this report.)

Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

x Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January to December 31, 2022

Section 1 - Conflict Minerals Disclosure

Item 1.01 Conflict Minerals Disclosure and Report

Teladoc Health, Inc. (the “Company”) has determined that from January 1, 2022 to December 31, 2022, certain Conflict Minerals (as defined by Item 1.01(d)(3) of Form SD) were necessary to the functionality and/or production of products that the Company manufactured or that it contracted to manufacture. Based on a reasonable country of origin inquiry, the Company has no reason to believe that such Conflict Minerals originated in the Democratic Republic of the Congo or an adjoining country sharing an internationally recognized border with the Democratic Republic of the Congo (together, “Covered Countries”).

The Company undertook a reasonable country of origin inquiry by sending a vendor questionnaire to each of its vendors that has been active within the past year, including new vendors. The questionnaire solicited information regarding each such vendor’s use of Conflict Minerals, its due diligence procedures with respect to its supply chain and the country of origin of any such Conflict Minerals. The Company also maintains a policy that it takes vendor responses to the questionnaire into account when assessing continuing vendor relationships.

None of the elicited responses implicated any of the Covered Countries as the country of origin for any Conflict Minerals used by the Company in products that it manufactured or contracted to manufacture during the period covered by this specialized disclosure report. Based on the Company’s review of the responses, it has no reason to believe that Conflict Minerals provided by its vendors may have originated in the Covered Countries.

This Conflict Minerals Disclosure is available through the “Investor Relations” and “Financial Info” links on the Company’s website at www.teladochealth.com. The information on the Company's website is not, and will not be deemed to be, a part of this report or incorporated into any of the Company's other filings with the Securities and Exchange Commission except where the Company expressly incorporates such information.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 30, 2023	TELADOC HEALTH, INC.

	By:	/s/ Adam C. Vandervoort
	Name:	Adam C. Vandervoort
	Title:	Chief Legal Officer and Secretary